​

ResMed (RMD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RMD Stock Forecast

ResMed stock forecast is as follows: an average price target of $233.50 (represents a -7.66% downside from RMD’s last price of $252.86) and a rating consensus of 'Hold', based on 22 wall street analysts offering a 1-year stock forecast.

RMD Price Target

The average price target for ResMed (RMD) is $233.50 based on 1-year price targets from 22 Wall Street analysts in the past 3 months, with a price target range of $280.00 to $180.00. This represents a potential -7.66% downside from RMD's last price of $252.86.

RMD Analyst Ratings

Hold

According to 22 Wall Street analysts, ResMed's rating consensus is 'Hold'. The analyst rating breakdown for RMD stock is 0 'Strong Buy' (0.00%), 9 'Buy' (40.91%), 12 'Hold' (54.55%), 1 'Sell' (4.55%), and 0 'Strong Sell' (0.00%).

ResMed Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 12, 2024Jonathan BlockStifel Nicolaus$250.00$242.513.09%-1.13%
Oct 01, 2024Craig Wong-PanRBC Capital$224.00$238.95-6.26%-11.41%
Sep 23, 2024Joe VruwinkRobert W. Baird$280.00$246.1813.74%10.73%
Sep 18, 2024Mike PolarkWolfe Research$180.00$250.88-28.25%-28.81%
Apr 10, 2024Craig Wong-PanRBC Capital$187.00$194.27-3.74%-26.05%
Apr 01, 2024Mike MatsonStifel Nicolaus$224.00$198.0313.11%-11.41%
Oct 27, 2023Suraj KaliaOppenheimer$175.00$134.6529.97%-30.79%
Sep 06, 2023Mike MatsonNeedham$180.00$153.8916.97%-28.81%
Jun 20, 2022Craig Wong-PanRBC Capital$244.00$197.5723.50%-3.50%
Apr 29, 2022RBC Capital$233.00$200.8116.03%-7.85%
Oct 14, 2021Suraj KaliaOppenheimer$312.00$253.7722.95%23.39%
Aug 04, 2021Sean LaamanMorgan Stanley$250.00$271.87-8.04%-1.13%
Jul 28, 2021Anthony PetroneJefferies$240.00$264.75-9.35%-5.09%

The latest ResMed stock forecast, released on Dec 12, 2024 by Jonathan Block from Stifel Nicolaus, set a price target of $250.00, which represents a 3.09% increase from the stock price at the time of the forecast ($242.51), and a -1.13% decrease from RMD last price ($252.86).

ResMed Price Target by Period

1M3M12M
# Anlaysts-16
Avg Price Target-$250.00$224.17
Last Closing Price$252.86$252.86$252.86
Upside/Downside-100.00%-1.13%-11.35%

In the current month, the average price target of ResMed stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ResMed's last price of $252.86. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Jan 10, 2025Piper SandlerNeutralNeutralInitialise
Oct 01, 2024RBC CapitalSector PerformSector PerformHold
Sep 24, 2024Wolfe ResearchSector PerformSector PerformHold
Sep 18, 2024NeedhamHoldHoldHold
Sep 18, 2024Wolfe ResearchPeer PerformUnderperformDowngrade
Sep 04, 2024RBC CapitalSector PerformSector PerformHold
Sep 04, 2024NeedhamBuyHoldDowngrade
Aug 27, 2024William BlairOutperformOutperformHold
Aug 02, 2024KeyBancOverweightOverweightHold
Jul 23, 2024RBC CapitalSector PerformSector PerformHold
Jun 25, 2024RBC CapitalSector PerformSector PerformHold
Jun 25, 2024OppenheimerOutperformPerformDowngrade
Apr 01, 2024NeedhamBuyBuyHold
Mar 27, 2024UBSSector PerformSector PerformHold
Jan 25, 2024NeedhamBuyBuyHold
Oct 27, 2023OppenheimerOutperformOutperformHold
Oct 27, 2023NeedhamBuyBuyHold
Oct 27, 2023Morgan StanleyEqual-WeightOverweightUpgrade
Aug 04, 2023KeyBancOverweightOverweightHold
May 22, 2023NeedhamBuyInitialise
May 22, 2023UBSBuyInitialise
May 22, 2023BWS FinancialBuyInitialise
May 22, 2023DaiwaBuyInitialise
May 22, 2023BTIGBuyInitialise
May 22, 2023Canaccord GenuityBuyInitialise
May 22, 2023Cowen & Co.OutperformInitialise
May 22, 2023BarclaysEqual-WeightInitialise
May 22, 2023Goldman SachsNeutralInitialise
Apr 28, 2023William BlairOutperformOutperformHold
Oct 20, 2022OppenheimerOutperformUpgrade
Oct 20, 2022Piper SandlerUnderweightNeutralUpgrade
Oct 20, 2022KeyBancOverweightUpgrade
Oct 20, 2022Bank of America SecuritiesBuyUpgrade
Oct 20, 2022Wolfe ResearchPeer PerformDowngrade
Oct 20, 2022Roth CapitalSellDowngrade
Oct 20, 2022Morgan StanleyEqual-WeightDowngrade
Oct 20, 2022Wells FargoEqual-WeightDowngrade
Oct 20, 2022Raymond JamesMarket PerformInitialise
Oct 20, 2022Argus ResearchHoldInitialise
Oct 20, 2022Deutsche BankSector WeightDowngrade
Oct 20, 2022Piper SandlerUnderweightDowngrade
Aug 12, 2022CitigroupNeutralDowngrade
Jun 06, 2022RBC CapitalOutperformUpgrade

ResMed's last stock rating was published by Piper Sandler on Jan 10, 2025. The company gave RMD a "Neutral" rating, the same as its previous rate.

ResMed Financial Forecast

ResMed Revenue Forecast

Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20
Revenue--------------$1.16B-$1.12B$1.12B$1.03B$950.29M$914.74M$864.50M$894.87M$904.01M$876.10M$768.77M$800.01M$751.94M$770.34M$769.46M
Avg Forecast$1.50B$1.46B$1.44B$1.41B$1.42B$1.39B$1.36B$1.32B$1.32B$1.30B$1.27B$1.19B$1.22B$1.17B$1.15B$1.10B$1.14B$1.05B$996.10M$949.78M$910.56M$904.59M$921.91M$856.61M$799.54M$797.03M$782.57M$710.06M$752.04M$724.07M
High Forecast$1.52B$1.48B$1.46B$1.43B$1.44B$1.41B$1.38B$1.33B$1.34B$1.32B$1.29B$1.19B$1.22B$1.17B$1.19B$1.13B$1.16B$1.07B$1.02B$949.78M$910.56M$904.59M$921.91M$856.61M$799.54M$797.03M$782.57M$710.06M$752.04M$724.07M
Low Forecast$1.47B$1.43B$1.41B$1.38B$1.39B$1.36B$1.34B$1.29B$1.29B$1.29B$1.24B$1.18B$1.22B$1.17B$1.13B$1.06B$1.12B$1.03B$985.09M$949.78M$910.56M$904.59M$921.91M$856.61M$799.54M$797.03M$782.57M$710.06M$752.04M$724.07M
# Analysts669999555121263361299555566669644
Surprise %--------------1.01%-0.98%1.06%1.04%1.00%1.00%0.96%0.97%1.06%1.10%0.96%1.02%1.06%1.02%1.06%

ResMed's average Quarter revenue forecast for Mar 24 based on 3 analysts is $1.17B, with a low forecast of $1.17B, and a high forecast of $1.17B. RMD's average Quarter revenue forecast represents a 0.98% increase compared to the company's last Quarter revenue of $1.16B (Dec 23).

ResMed EBITDA Forecast

Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20
# Analysts669999555121263361299555566669644
EBITDA--------------$275.09M-$333.76M$347.04M$342.56M$319.77M$300.40M$285.87M$280.94M$306.41M$290.24M$271.76M$264.58M$272.58M$266.80M$248.09M
Avg Forecast$497.95M$484.05M$477.47M$466.51M$470.19M$459.93M$452.09M$435.71M$436.65M$429.14M$419.59M$392.70M$403.69M$367.05M$381.16M$365.59M$378.27M$333.68M$325.96M$318.22M$305.08M$303.35M$308.89M$287.01M$267.88M$265.35M$262.20M$237.91M$251.97M$191.38M
High Forecast$504.89M$490.79M$484.13M$473.01M$476.75M$466.34M$458.39M$441.78M$442.73M$435.80M$426.25M$393.42M$403.69M$440.46M$394.31M$373.93M$383.54M$400.42M$391.15M$318.22M$305.08M$364.02M$308.89M$287.01M$267.88M$318.41M$262.20M$237.91M$251.97M$229.66M
Low Forecast$488.61M$474.97M$468.52M$457.76M$461.37M$451.30M$443.61M$427.54M$428.46M$425.82M$411.72M$391.98M$403.69M$293.64M$374.59M$350.57M$371.17M$266.95M$260.77M$318.22M$305.08M$242.68M$308.89M$287.01M$267.88M$212.28M$262.20M$237.91M$251.97M$153.11M
Surprise %--------------0.72%-0.88%1.04%1.05%1.00%0.98%0.94%0.91%1.07%1.08%1.02%1.01%1.15%1.06%1.30%

3 analysts predict RMD's average Quarter EBITDA for Mar 24 to be $367.05M, with a high of $440.46M and a low of $293.64M. This is 33.43% upper than ResMed's previous annual EBITDA (Dec 23) of $275.09M.

ResMed Net Income Forecast

Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20
# Analysts669999555121263361299555566669644
Net Income--------------$208.80M-$229.66M$232.50M$224.91M$210.48M$195.06M$179.01M$201.75M$203.61M$195.10M$-78.48M$179.51M$178.37M$177.84M$163.14M
Avg Forecast$423.51M$407.82M$400.81M$382.13M$390.92M$383.87M$374.83M$359.59M$360.73M$354.28M$342.17M$303.19M$307.41M$231.86M$262.16M$238.98M$247.84M$210.78M$229.23M$226.46M$212.72M$191.62M$220.69M$202.40M$190.87M$-76.63M$188.02M$149.80M$161.77M$125.85M
High Forecast$431.18M$415.21M$408.07M$389.06M$398.01M$390.83M$381.63M$366.11M$367.27M$363.25M$348.15M$303.47M$307.50M$278.23M$275.19M$247.83M$252.33M$252.94M$275.07M$226.46M$212.72M$229.94M$220.69M$202.40M$190.87M$-61.30M$188.02M$149.80M$161.77M$151.02M
Low Forecast$413.18M$397.88M$391.04M$372.82M$381.39M$374.51M$365.70M$350.83M$351.94M$342.32M$337.69M$302.91M$307.32M$185.49M$253.47M$228.65M$241.80M$168.62M$183.38M$226.46M$212.72M$153.29M$220.69M$202.40M$190.87M$-91.95M$188.02M$149.80M$161.77M$100.68M
Surprise %--------------0.80%-0.93%1.10%0.98%0.93%0.92%0.93%0.91%1.01%1.02%1.02%0.95%1.19%1.10%1.30%

ResMed's average Quarter net income forecast for Mar 24 is $231.86M, with a range of $185.49M to $278.23M. RMD's average Quarter net income forecast represents a 11.04% increase compared to the company's last Quarter net income of $208.80M (Dec 23).

ResMed SG&A Forecast

Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20
# Analysts669999555121263361299555566669644
SG&A--------------$222.16M-$240.69M$228.46M$211.67M$193.93M$194.89M$182.40M$185.36M$176.72M$181.48M$160.45M$169.47M$158.99M$165.38M$172.44M
Avg Forecast$314.96M$306.17M$302.01M$295.08M$297.41M$290.91M$285.96M$275.60M$276.19M$271.44M$265.40M$248.39M$255.34M$236.25M$241.09M$231.25M$239.26M$214.77M$210.61M$199.05M$190.83M$195.25M$193.21M$179.53M$167.57M$156.66M$164.01M$148.81M$157.61M$133.03M
High Forecast$319.35M$310.44M$306.22M$299.19M$301.55M$294.97M$289.95M$279.44M$280.04M$275.65M$269.61M$248.85M$255.34M$283.50M$249.41M$236.52M$242.60M$257.72M$252.73M$199.05M$190.83M$234.30M$193.21M$179.53M$167.57M$187.99M$164.01M$148.81M$157.61M$159.63M
Low Forecast$309.06M$300.43M$296.35M$289.54M$291.83M$285.46M$280.60M$270.43M$271.01M$269.34M$260.42M$247.94M$255.34M$189.00M$236.94M$221.74M$234.78M$171.82M$168.48M$199.05M$190.83M$156.20M$193.21M$179.53M$167.57M$125.32M$164.01M$148.81M$157.61M$106.42M
Surprise %--------------0.92%-1.01%1.06%1.01%0.97%1.02%0.93%0.96%0.98%1.08%1.02%1.03%1.07%1.05%1.30%

ResMed's average Quarter SG&A projection for Mar 24 is $236.25M, based on 3 Wall Street analysts, with a range of $189.00M to $283.50M. The forecast indicates a 6.34% rise compared to RMD last annual SG&A of $222.16M (Dec 23).

ResMed EPS Forecast

Jun 27Mar 27Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20
# Analysts669999555121263361299555566669644
EPS----------------$1.56$1.58$1.53$1.44$1.33$1.22$1.38$1.40$1.34$-0.54$1.24$1.23$1.23$1.13
Avg Forecast$2.87$2.76$2.72$2.59$2.65$2.60$2.54$2.44$2.44$2.40$2.32$2.05$2.08$1.93$1.78$1.62$1.68$1.61$1.61$1.53$1.44$1.46$1.50$1.37$1.29$1.29$1.27$1.02$1.10$1.03
High Forecast$2.92$2.81$2.76$2.64$2.70$2.65$2.59$2.48$2.49$2.46$2.36$2.06$2.08$1.93$1.86$1.68$1.71$1.63$1.66$1.53$1.44$1.47$1.50$1.37$1.29$1.29$1.27$1.02$1.10$1.03
Low Forecast$2.80$2.70$2.65$2.53$2.58$2.54$2.48$2.38$2.38$2.32$2.29$2.05$2.08$1.93$1.72$1.55$1.64$1.57$1.59$1.53$1.44$1.44$1.50$1.37$1.29$1.29$1.27$1.02$1.10$1.03
Surprise %----------------0.93%0.98%0.95%0.94%0.92%0.84%0.92%1.02%1.04%-0.42%0.97%1.21%1.12%1.09%

According to 12 Wall Street analysts, ResMed's projected average Quarter EPS for Sep 23 is $1.62, with a low estimate of $1.55 and a high estimate of $1.68. This represents a 3.79% increase compared to RMD previous annual EPS of $1.56 (Jun 23).

ResMed Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
COOCooper Companies$98.00$250.86155.98%Buy
STAASTAAR Surgical$24.19$54.58125.63%Buy
TFXTeleflex$180.58$257.6742.69%Buy
BAXBaxter$32.78$43.0031.18%Hold
EMBCEmbecta$18.40$23.0025.00%Buy
HOLXHologic$71.41$87.3322.29%Buy
ALCAlcon$91.38$107.8017.97%Buy
WSTWest Pharmaceutical Services$339.57$393.0015.73%Buy
ICUIICU Medical$168.30$190.5013.19%Buy
BDXBecton, Dickinson and$246.90$278.7512.90%Buy
MMSIMerit Medical Systems$108.48$105.60-2.65%Buy
RMDResMed$252.86$233.50-7.66%Hold

RMD Forecast FAQ

Is ResMed a good buy?

No, according to 22 Wall Street analysts, ResMed (RMD) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 40.91% of RMD's total ratings.

What is RMD's price target?

ResMed (RMD) average price target is $233.5 with a range of $180 to $280, implying a -7.66% from its last price of $252.86. The data is based on 22 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will ResMed stock go up soon?

According to Wall Street analysts' prediction for RMD stock, the company can go down by -7.66% (from the last price of $252.86 to the average price target of $233.5), up by 10.73% based on the highest stock price target, and down by -28.81% based on the lowest stock price target.

Can ResMed stock reach $400?

RMD's average twelve months analyst stock price target of $233.5 does not support the claim that ResMed can reach $400 in the near future.

What are ResMed's analysts' financial forecasts?

ResMed's analysts financial forecasts for the fiscal year (Jun 2026) are as follows: average revenue is $5.49B (high $5.56B, low $5.38B), average EBITDA is $1.82B (high $1.84B, low $1.78B), average net income is $1.51B (high $1.54B, low $1.47B), average SG&A $1.15B (high $1.17B, low $1.13B), and average EPS is $10.23 (high $10.41, low $9.98). RMD's analysts financial forecasts for the fiscal year (Jun 2027) are as follows: average revenue is $5.81B (high $5.89B, low $5.7B), average EBITDA is $1.93B (high $1.95B, low $1.89B), average net income is $1.61B (high $1.64B, low $1.57B), average SG&A $1.22B (high $1.24B, low $1.2B), and average EPS is $10.94 (high $11.14, low $10.67).

Did the RMD's actual financial results beat the analysts' financial forecasts?

Based on ResMed's last annual report (Jun 2023), the company's revenue was $4.22B, beating the average analysts forecast of $4.14B by 2.05%. Apple's EBITDA was $1.34B, missing the average prediction of $1.36B by -1.22%. The company's net income was $897.56M, missing the average estimation of $914.31M by -1.83%. Apple's SG&A was $874M, beating the average forecast of $863.69M by 1.19%. Lastly, the company's EPS was $0, missing the average prediction of $6.43 by -100.00%. In terms of the last quarterly report (Dec 2023), ResMed's revenue was $1.16B, beating the average analysts' forecast of $1.15B by 1.08%. The company's EBITDA was $275.09M, missing the average prediction of $381.16M by -27.83%. ResMed's net income was $208.8M, missing the average estimation of $262.16M by -20.35%. The company's SG&A was $222.16M, missing the average forecast of $241.09M by -7.86%. Lastly, the company's EPS was $0, missing the average prediction of $1.78 by -100.00%